Product Images Zolmitriptan

The text provides a figure (Figure 1) showing the estimated probability of achieving initial headache response within four hours of treatment in pooled studies 2, 3, and 5 for various doses of zolmitriptan and placebo. The different doses of zolmitriptan include 1 mg, 2.5 mg, and 5 mg. The chart indicates that the probability of achieving a reduction in headache severity from moderate or severe pain to mild or no headache within four hours of treatment is highest (70%) for a 5 mg dose of zolmitriptan compared to other doses and placebo. The text describes the chart's main message, and therefore, No further details are available.*

This is a package of Zolmitriptan Tablets, USP, which includes 6 (1 x 6) unit-dose tablets. The tablets are manufactured in India and distributed by Rising Pharma Holdings, Inc. The package contains information on the product, such as the National Drug Code (NDC) number and a Production Identification (PI) number, but also includes a warning not to print over the dotted-s area. The additional text appears to be illegible and of unknown relevance.*

This is a description of a medication package containing 3 (1x 3) unit-dose tablets of Zolmitriptan Tablets, USP. The package is distributed by Rising Pharma Holdings, Inc from East Brunswick and is made in India. The package includes a code: TS/DRUGS/22/2009 and NDC 16571-804-13. There are instructions on the package regarding over printing and the unvarnished zone. There is also illegible text in the middle section of the package.*